Show simple item record

dc.contributor.authorBibevski, Steve
dc.contributor.authorRuzmetov, Mark
dc.contributor.authorFortuna, Randall S.
dc.contributor.authorTurrentine, Mark W.
dc.contributor.authorBrown, John W.
dc.contributor.authorOhye, Richard G.
dc.date.accessioned2017-05-25T00:22:04Z
dc.date.available2017-05-25T00:22:04Z
dc.date.issued2017-03
dc.identifier.citationPerformance of SynerGraft Decellularized Pulmonary Allografts Compared With Standard Cryopreserved Allografts: Results From Multiinstitutional Data 2017, 103 (3):869 The Annals of Thoracic Surgeryen
dc.identifier.issn00034975
dc.identifier.doi10.1016/j.athoracsur.2016.07.068
dc.identifier.urihttp://hdl.handle.net/10150/623618
dc.description.abstractBackground. Structural deterioration of allografts over time is believed to be at least partly related to an immune response mounted against human leukocyte antigen specific to the transplanted tissue. SynerGraft (SG) processing (CryoLife, Kennesaw, GA) is a technology that decellularizes an allograft leaving only connective tissue, therefore, reducing immunogenicity and potentially increasing durability of the implant. Methods. We performed a retrospective review of 163 SG patients and 124 standard allograft controls from 3 medical centers. Patient demographics were tabulated, and conduit stenosis and insufficiency were measured by echocardiography. Results. There were 28 deaths (15 of 163 [9%] SG patients vs 13 of 124 [11%] standard patients; p = 0.72), but no deaths were attributed to structural failure of the conduit. The actuarial survival for SG vs standard cohorts was not different at 5 and 10 years. Among the 274 hospital survivors, 17% SG vs 42% standard had evidence for significant conduit dysfunction at the most recent followup or before conduit replacement. Freedom from conduit dysfunction was significantly worse at 10 years in the standard group (58%) than in the SGgroup (83%, p < 0.001). Conclusions. This study represents a multiinstitutional retrospective comparison of SG and standard cry-opreserved allografts used in right ventricular outflow tract reconstruction in a broad range of patient ages. Our results demonstrate that at an intermediate-term to longterm follow-up, conduit dysfunction and pulmonary insufficiency and stenosis are higher among patients receiving standard allografts. We postulate that the improved durability of SG is related to decreased immunogenicity of the SG technology.
dc.language.isoenen
dc.publisherELSEVIER SCIENCE INCen
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0003497516309778en
dc.rights© 2016 by The Society of Thoracic Surgeons Published by Elsevieren
dc.titlePerformance of SynerGraft Decellularized Pulmonary Allografts Compared With Standard Cryopreserved Allografts: Results From Multiinstitutional Dataen
dc.typeArticleen
dc.contributor.departmentSection of Pediatric Cardiothoracic Surgery, Banner Children’s Hospital, University of Arizona College of Medicine, Phoenix, Arizonaen
dc.identifier.journalThe Annals of Thoracic Surgeryen
dc.description.note12 month embargo; Available online 24 October 2016en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal accepted manuscripten
refterms.dateFOA2017-10-25T00:00:00Z
html.description.abstractBackground. Structural deterioration of allografts over time is believed to be at least partly related to an immune response mounted against human leukocyte antigen specific to the transplanted tissue. SynerGraft (SG) processing (CryoLife, Kennesaw, GA) is a technology that decellularizes an allograft leaving only connective tissue, therefore, reducing immunogenicity and potentially increasing durability of the implant. Methods. We performed a retrospective review of 163 SG patients and 124 standard allograft controls from 3 medical centers. Patient demographics were tabulated, and conduit stenosis and insufficiency were measured by echocardiography. Results. There were 28 deaths (15 of 163 [9%] SG patients vs 13 of 124 [11%] standard patients; p = 0.72), but no deaths were attributed to structural failure of the conduit. The actuarial survival for SG vs standard cohorts was not different at 5 and 10 years. Among the 274 hospital survivors, 17% SG vs 42% standard had evidence for significant conduit dysfunction at the most recent followup or before conduit replacement. Freedom from conduit dysfunction was significantly worse at 10 years in the standard group (58%) than in the SGgroup (83%, p < 0.001). Conclusions. This study represents a multiinstitutional retrospective comparison of SG and standard cry-opreserved allografts used in right ventricular outflow tract reconstruction in a broad range of patient ages. Our results demonstrate that at an intermediate-term to longterm follow-up, conduit dysfunction and pulmonary insufficiency and stenosis are higher among patients receiving standard allografts. We postulate that the improved durability of SG is related to decreased immunogenicity of the SG technology.


Files in this item

Thumbnail
Name:
Fortuna_manuscript.pdf
Size:
117.3Kb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record